The FDA's new fast-track drug approval program is sparking intense debate and raising serious concerns. Could this be the moment when politics overshadows science in drug approvals?
In a move that has sent shockwaves through the agency, the Food and Drug Administration (FDA) is dramatically shortening the review process for certain drugs, a decision championed by the Trump administration. But here's where it gets controversial: this expedited program, led by FDA Commissioner Marty Makary, is causing unease among staff already reeling from layoffs, buyouts, and leadership changes. According to insiders, the program’s lack of transparency and legal clarity is fueling anxiety and confusion.
One of the most pressing issues? Who has the authority to approve these drugs? Traditionally, drug approvals are handled by FDA scientists and their supervisors, not political appointees. Yet, under the Commissioner's National Priority Voucher program, which promises approval in as little as one month for drugs deemed in the 'U.S. national interest,' the lines of authority are blurred. This has left even top officials questioning the legality of their roles in the process.
And this is the part most people miss: the FDA's standard drug review process, which typically takes six to ten months, is already the fastest in the world. Dr. Aaron Kesselheim, a Harvard Medical School professor, points out, 'The idea of conducting a thorough review in one to two months simply lacks scientific precedent. The FDA cannot maintain its rigorous standards in such a short timeframe, nor does it have the resources to do so.'
The program’s rushed nature has already led to delays in reviewing two drugs due to safety concerns, including a patient death. Despite this, the program remains popular at the White House, where it’s often tied to drug pricing concessions. For instance, when Eli Lilly and Novo Nordisk agreed to lower prices on their obesity drugs, FDA staffers were pressured to fast-track vouchers in time for a presidential announcement. This has sparked fears that drug approvals, once grounded in objective standards, are now vulnerable to political influence.
Is this a necessary acceleration of critical treatments, or a dangerous compromise of safety standards? Paul Kim, a former FDA attorney, warns, 'It’s unprecedented to have such an opaque process, one that’s clearly open to politicization.'
Adding to the controversy, the program isn’t formally codified in federal rules. Instead, details are largely confined to an agency website, and drugmakers apply with a mere 350-word statement. This lack of structure has led key officials, including former drug director Dr. George Tidmarsh and principal deputy commissioner Dr. Sara Brenner, to refuse to sign off on approvals due to legal concerns.
The program’s expansion, from an initial pilot of five drugs to 18 awarded vouchers (with more pending), is stretching the FDA’s resources thin. This is especially challenging given that 20% of the drug center’s staff has left in the past year. Meanwhile, drugmakers are pushing for even faster timelines, sometimes bypassing critical regulatory steps. For example, Eli Lilly pressured the FDA to skip the standard 60-day prefiling period for its anti-obesity pill, a process in place for over 30 years.
Should drug approvals prioritize speed over safety? Former reviewers argue that skipping steps undermines the FDA’s core mission: scientifically confirming a drug’s safety and effectiveness. Dr. Kesselheim cautions, 'This program may not outlast the current administration. The hope is that we’ll return to scientifically and legally sound principles.'
As the debate rages on, one question remains: Are we sacrificing long-term safety for short-term gains? Share your thoughts in the comments—do you think this program is a step forward or a risky gamble?
